Physician profile
Steven Tee
NPI 1811980584
$8,745.68
in general payments reported to CMS, 2019-2025
37 companies · $50.00 in 2025
The $50.00 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,692 · 2020: $1,004 · 2025: $50.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,356.70 | 2019-2020 | |
| Novo Nordisk INC | $1,097.51 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $666.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $647.73 | 2019-2020 | |
| Abbott Laboratories | $552.05 | 2019 | |
| Pfizer INC. | $476.36 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.58 | 2019-2020 | |
| Lilly USA, LLC | $331.30 | 2019 | |
| Gilead Sciences, INC. | $320.09 | 2019 | |
| Amgen INC. | $292.85 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $278.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $245.11 | 2019 | |
| Mylan Specialty L.P. | $228.12 | 2019 | |
| Merck Sharp & Dohme LLC | $203.27 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $177.48 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $174.85 | 2019 | |
| Boston Scientific Corporation | $155.94 | 2019 | |
| Biotronik INC. | $144.65 | 2019 | |
| Allergan, INC. | $144.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.04 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.60 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $92.44 | 2019 | |
| Hikma Pharmaceuticals USA | $70.24 | 2019 | |
| Arbor Pharmaceuticals, INC. | $68.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.95 | 2019 | |
| Amarin Pharma, INC. | $65.31 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $42.88 | 2019-2020 | |
| Akcea Therapeutics, INC. | $41.49 | 2019 | |
| Antares Pharma, INC. | $39.43 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $33.95 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $23.76 | 2019 | |
| Glaxosmithkline, LLC. | $22.34 | 2019 | |
| Edwards Lifesciences Corporation | $22.21 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.35 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $16.81 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.64 | 2020 | |
| United Therapeutics Corporation | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Tee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.